Skip to main content
PMC home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1986 Mar-Apr;59(2):97–106.

Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing?

C A Dinarello, P Conti, J W Mier
PMCID: PMC2590122  PMID: 3488622

Abstract

Interleukin-1 (IL-1) represents a family of polypeptides with a wide range of biological activities. cDNA from two gene products has been cloned; there are probably more. The human IL-1 family plays an important role in the pathogenesis of many diseases and functions as a key mediator of host response to various infectious, inflammatory, neoplastic, and immunologic challenges. Recombinant mouse (pI 5) and recombinant human (pI 7) IL-1s are being used to confirm the multiple biological properties of IL-1s. Some IL-1 biological activities seem to be involved with mechanisms of host tumor killing. Incubating purified or recombinant human IL-1 with human peripheral blood mononuclear cells in the presence of IL-2 or interferon-alpha results in a synergistic enhancement of certain tumor cells. More recent results indicate that IL-1 exhibits direct cytotoxicity for tumor cells in vitro. The peripheral blood mononuclear cells of patients with tumors demonstrate decreased production of IL-1 when challenged with endotoxin and show a comparable decrease in natural killer activity; adding exogenous IL-1 reverses this defect in these patients. However, induction of hepatic acute-phase proteins such as serum amyloid A serves as a negative feedback since the amyloid protein suppresses natural killer activity. Moreover, natural killer cell activity in the presence of IL-1 or interferon-alpha is suppressed by incubating temperatures of 39 degrees C. This effect is not reversed by inhibitors of prostaglandin synthesis. IL-1 is clearly important to host defense against malignancy, but some aspects of IL-1 biology seem to exert a contrary influence.

Full text

PDF
97

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreesen R., Osterholz J., Schulz A., Löhr G. W. Enhancement of spontaneous and lymphokine activated human macrophage cytotoxicity by hyperthermia. Blut. 1983 Oct;47(4):225–229. doi: 10.1007/BF00320841. [DOI] [PubMed] [Google Scholar]
  2. Atkins E. Fever: the old and the new. J Infect Dis. 1984 Mar;149(3):339–348. doi: 10.1093/infdis/149.3.339. [DOI] [PubMed] [Google Scholar]
  3. Auron P. E., Webb A. C., Rosenwasser L. J., Mucci S. F., Rich A., Wolff S. M., Dinarello C. A. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7907–7911. doi: 10.1073/pnas.81.24.7907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baracos V., Rodemann H. P., Dinarello C. A., Goldberg A. L. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med. 1983 Mar 10;308(10):553–558. doi: 10.1056/NEJM198303103081002. [DOI] [PubMed] [Google Scholar]
  5. Coley W. B. FURTHER OBSERVATIONS ON THE CONSERVATIVE TREATMENT OF SARCOMA OF THE LONG BONES. Ann Surg. 1919 Dec;70(6):633–660. doi: 10.1097/00000658-191912000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dempsey R. A., Dinarello C. A., Mier J. W., Rosenwasser L. J., Allegretta M., Brown T. E., Parkinson D. R. The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol. 1982 Dec;129(6):2504–2510. [PubMed] [Google Scholar]
  7. Dinarello C. A. An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol. 1985 Sep;5(5):287–297. doi: 10.1007/BF00918247. [DOI] [PubMed] [Google Scholar]
  8. Dinarello C. A., Bernheim H. A., Duff G. W., Le H. V., Nagabhushan T. L., Hamilton N. C., Coceani F. Mechanisms of fever induced by recombinant human interferon. J Clin Invest. 1984 Sep;74(3):906–913. doi: 10.1172/JCI111508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dinarello C. A., Bishai I., Rosenwasser L. J., Coceani F. The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). Int J Immunopharmacol. 1984;6(1):43–50. doi: 10.1016/0192-0561(84)90033-x. [DOI] [PubMed] [Google Scholar]
  10. Dinarello C. A. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984 Nov 29;311(22):1413–1418. doi: 10.1056/NEJM198411293112205. [DOI] [PubMed] [Google Scholar]
  11. Dinarello C. A. Interleukin-1. Rev Infect Dis. 1984 Jan-Feb;6(1):51–95. doi: 10.1093/clinids/6.1.51. [DOI] [PubMed] [Google Scholar]
  12. Dinarello C. A., Marnoy S. O., Rosenwasser L. J. Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J Immunol. 1983 Feb;130(2):890–895. [PubMed] [Google Scholar]
  13. Dinarello C. A., Wolff S. M. Molecular basis of fever in humans. Am J Med. 1982 May;72(5):799–819. doi: 10.1016/0002-9343(82)90548-4. [DOI] [PubMed] [Google Scholar]
  14. Duff G. W., Durum S. K. Fever and immunoregulation: hyperthermia, interleukins 1 and 2, and T-cell proliferation. Yale J Biol Med. 1982 Sep-Dec;55(5-6):437–442. [PMC free article] [PubMed] [Google Scholar]
  15. Duff G. W., Durum S. K. The pyrogenic and mitogenic actions of interleukin-1 are related. Nature. 1983 Aug 4;304(5925):449–451. doi: 10.1038/304449a0. [DOI] [PubMed] [Google Scholar]
  16. Gery I., Waksman B. H. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med. 1972 Jul 1;136(1):143–155. doi: 10.1084/jem.136.1.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hall E. J., Roizin-Towle L. Biological effects of heat. Cancer Res. 1984 Oct;44(10 Suppl):4708s–4713s. [PubMed] [Google Scholar]
  18. Hanson D. F., Murphy P. A., Silicano R., Shin H. S. The effect of temperature on the activation of thymocytes by interleukins I and II. J Immunol. 1983 Jan;130(1):216–221. [PubMed] [Google Scholar]
  19. Herberman R. B. Natural killer (NK) cells and their possible roles in resistance against disease. Clin Immunol Rev. 1981;1(1):1–65. [PubMed] [Google Scholar]
  20. Herman J., Kew M. C., Rabson A. R. Defective interleukin-1 production by monocytes from patients with malignant disease. Interferon increases IL-1 production. Cancer Immunol Immunother. 1984;16(3):182–185. doi: 10.1007/BF00205426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jampel H. D., Duff G. W., Gershon R. K., Atkins E., Durum S. K. Fever and immunoregulation. III. Hyperthermia augments the primary in vitro humoral immune response. J Exp Med. 1983 Apr 1;157(4):1229–1238. doi: 10.1084/jem.157.4.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kampschmidt R. F. Infection, inflammation, and interleukin 1 (IL-1). Lymphokine Res. 1983;2(3):97–102. [PubMed] [Google Scholar]
  23. Krueger J. M., Walter J., Dinarello C. A., Wolff S. M., Chedid L. Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol. 1984 Jun;246(6 Pt 2):R994–R999. doi: 10.1152/ajpregu.1984.246.6.R994. [DOI] [PubMed] [Google Scholar]
  24. Kurt-Jones E. A., Beller D. I., Mizel S. B., Unanue E. R. Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1204–1208. doi: 10.1073/pnas.82.4.1204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lepe-Zuniga J. L., Gery I. Production of intra- and extracellular interleukin-1 (IL-1) by human monocytes. Clin Immunol Immunopathol. 1984 May;31(2):222–230. doi: 10.1016/0090-1229(84)90242-3. [DOI] [PubMed] [Google Scholar]
  26. Li D. J., Hahn G. M. Responses of RIF tumors to heat and drugs: dependence on tumor size. Cancer Treat Rep. 1984 Sep;68(9):1149–1151. [PubMed] [Google Scholar]
  27. Lipsky P. E., Thompson P. A., Rosenwasser L. J., Dinarello C. A. The role of interleukin 1 in human B cell activation: inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen. J Immunol. 1983 Jun;130(6):2708–2714. [PubMed] [Google Scholar]
  28. Lomedico P. T., Gubler U., Hellmann C. P., Dukovich M., Giri J. G., Pan Y. C., Collier K., Semionow R., Chua A. O., Mizel S. B. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. 1984 Nov 29-Dec 5Nature. 312(5993):458–462. doi: 10.1038/312458a0. [DOI] [PubMed] [Google Scholar]
  29. Lotze M. T., Frana L. W., Sharrow S. O., Robb R. J., Rosenberg S. A. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985 Jan;134(1):157–166. [PubMed] [Google Scholar]
  30. Luger T. A., Charon J. A., Colot M., Micksche M., Oppenheim J. J. Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells. J Immunol. 1983 Aug;131(2):816–820. [PubMed] [Google Scholar]
  31. Matsushima K., Durum S. K., Kimball E. S., Oppenheim J. J. Purification of human interleukin 1 from human monocyte culture supernatants and identity of thymocyte comitogenic factor, fibroblast-proliferation factor, acute-phase protein-inducing factor, and endogenous pyrogen. Cell Immunol. 1985 May;92(2):290–301. doi: 10.1016/0008-8749(85)90010-3. [DOI] [PubMed] [Google Scholar]
  32. Miller T. R., Nicholson J. T. End results in reticulum cell sarcoma of bone treated by bacterial toxin therapy alone or combined with surgery and-or radiotherapy (47 cases) or with concurrent infection (5 cases). Cancer. 1971 Mar;27(3):524–548. doi: 10.1002/1097-0142(197103)27:3<524::aid-cncr2820270305>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  33. Miossec P., Yu C. L., Ziff M. Lymphocyte chemotactic activity of human interleukin 1. J Immunol. 1984 Oct;133(4):2007–2011. [PubMed] [Google Scholar]
  34. Mizel S. B. Interleukin 1 and T cell activation. Immunol Rev. 1982;63:51–72. doi: 10.1111/j.1600-065x.1982.tb00411.x. [DOI] [PubMed] [Google Scholar]
  35. Muraguchi A., Kehrl J. H., Butler J. L., Fauci A. S. Regulation of human B-cell activation, proliferation, and differentiation by soluble factors. J Clin Immunol. 1984 Sep;4(5):337–347. doi: 10.1007/BF00917136. [DOI] [PubMed] [Google Scholar]
  36. Müllbacher A. Hyperthermia and the generation and activity of murine influenza-immune cytotoxic T cells in vitro. J Virol. 1984 Dec;52(3):928–931. doi: 10.1128/jvi.52.3.928-931.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Neufeld H. A., Pace J. G., Kaminski M. V., George D. T., Jahrling P. B., Wannemacher R. W., Jr, Beisel W. R. A probable endocrine basis for the depression of ketone bodies during infectious or inflammatory state in rats. Endocrinology. 1980 Aug;107(2):596–601. doi: 10.1210/endo-107-2-596. [DOI] [PubMed] [Google Scholar]
  38. Onozaki K., Matsushima K., Aggarwal B. B., Oppenheim J. J. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985 Dec;135(6):3962–3968. [PubMed] [Google Scholar]
  39. Pepys M. B., Baltz M. L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212. doi: 10.1016/s0065-2776(08)60379-x. [DOI] [PubMed] [Google Scholar]
  40. Ramadori G., Sipe J. D., Dinarello C. A., Mizel S. B., Colten H. R. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med. 1985 Sep 1;162(3):930–942. doi: 10.1084/jem.162.3.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Roberts N. J., Jr Temperature and host defense. Microbiol Rev. 1979 Jun;43(2):241–259. doi: 10.1128/mr.43.2.241-259.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Saklatvala J., Pilsworth L. M., Sarsfield S. J., Gavrilovic J., Heath J. K. Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein. Biochem J. 1984 Dec 1;224(2):461–466. doi: 10.1042/bj2240461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sauder D. N., Mounessa N. L., Katz S. I., Dinarello C. A., Gallin J. I. Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol. 1984 Feb;132(2):828–832. [PubMed] [Google Scholar]
  44. Scala G., Kuang Y. D., Hall R. E., Muchmore A. V., Oppenheim J. J. Accessory cell function of human B cells. I. Production of both interleukin 1-like activity and an interleukin 1 inhibitory factor by an EBV-transformed human B cell line. J Exp Med. 1984 Jun 1;159(6):1637–1652. doi: 10.1084/jem.159.6.1637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sebag J., Reed W. P., Williams R. C., Jr Effect of temperature on bacterial killing by serum and by polymorphonuclear leukocytes. Infect Immun. 1977 Jun;16(3):947–954. doi: 10.1128/iai.16.3.947-954.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Uchida A., Hoshino T. Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapy. Int J Cancer. 1980 Oct 15;26(4):401–404. doi: 10.1002/ijc.2910260403. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES